



Studies on the resorcyates: biomimetic total syntheses of (+)-montagnetol and (+)-erythrin

Jean-François Basset^a, Colin Leslie^b, Dieter Hamprecht^b, Andrew J. P. White^a, Anthony G. M. Barrett^{a,*}

^a Department of Chemistry, Imperial College, London SW7 2AZ, England, United Kingdom

^b GlaxoSmithKline Centro Ricerche, Via Fleming 4, I-37135 Verona, Italy

ARTICLE INFO

Article history:

Received 11 October 2009

Revised 22 November 2009

Accepted 30 November 2009

Available online 3 December 2009

ABSTRACT

6-(2,4-Dioxopentyl)-2,2-trimethyl-4H-1,3-dioxin-4-one on reflux in toluene gave MeCOCH₂COCH₂COCH=C=O, which cyclized to 6-(2-oxopropyl)-4-hydroxy-2H-pyran-2-one or was trapped with alcohols to produce resorcyate esters. The method was used for the synthesis of both enantiomers of montagnetol and erythrin.

© 2009 Elsevier Ltd. All rights reserved.

The orsellinic acid unit **1** occurs widely in natural products, including montagnetol (**2**) and the anti-oxidant¹ erythrin (**3**), both isolated from the lichen *Roccella montagnei* (Fig. 1).² The structures of montagnetol (**2**) and erythrin (**3**) were confirmed by synthesis,³ although the absolute stereochemistry has not yet been assigned. Herein, we report a convergent, novel synthesis of diketo-1,3-dioxinone **10**, its varied cyclization reactions, and its application to the synthesis of both enantiomers of (+)-montagnetol (**2**) and (+)-erythrin (**3**) thereby determining the absolute configuration of these natural products.

Recently, we reported efficient biomimetic syntheses of bioactive resorcyate natural products **4** via thermolysis, ketene trapping, and aromatization, starting from dioxinones **5** (Scheme 1).⁴

In the process of optimizing the aromatization step in the synthesis of these natural products, a model system, diketo-1,3-dioxinone **10** was examined. It was found that **10** can undergo different cyclization reactions depending on the reaction conditions.

Dioxinone **10** was synthesized by thermolysis of commercially available dioxinone **6**, which underwent a retro-Diels–Alder⁵ reaction at 90 °C to form acyl-ketene **7**, which was trapped with benzotriazole **8** to form amide **9** in quantitative yield.⁶ Subsequent crossed Claisen condensation⁷ via reaction of the lithium enolate from dioxinone **6** with amide **9** gave diketo-1,3-dioxinone **10** as a 5:95 mixture of keto–enol tautomers in 53% yield over two steps (Scheme 2).⁸

Dioxinone **10** undergoes cyclization using triethylamine, 1,4-diazabicyclo(2.2.2)octane, or *N,N*-4-dimethylaminopyridine to give the benzo[1,3]dioxinone **11** (Scheme 3). Alternatively, thermolysis in toluene containing methanol and aromatization with cesium carbonate followed by acidification gave the resorcyate **13** (87%). Finally, thermolysis of dioxinone **10** alone in toluene solution gave the pyrone **14** (68%).

The thermolytic ketene generation, trapping, and aromatization were applied to the total synthesis of (+)-montagnetol (**2**) and (+)-erythrin (**3**), respectively.

Thermolysis of dioxinone **10** in the presence of benzyl-protected erithritols **15a**¹⁰ and **15b** gave the triketo-esters **16a** and **16b**, respectively.¹¹ NMR analysis in CDCl₃ showed these compounds to exist as mixtures of keto and enol tautomers.¹² Aldol cyclization and aromatization followed by hydrogenolysis of the benzyl groups gave **18** and (+)-montagnetol (**2**), respectively (Scheme 4).

Reaction between dioxinone **10** and phenol **17a** at 110 °C failed to give the corresponding aryl triketo-ester, indicating that the






Figure 1. Natural products containing the orsellinic acid unit.




Scheme 1. Retrosynthetic approach to build 6-alkyl-2,4-dihydroxybenzoic acid unit **4**.

* Corresponding author.


E-mail address: agm.barrett@imperial.ac.uk (A.G.M. Barrett).



Scheme 2. Synthesis of diketo-1,3-dioxinone **10**.




Scheme 3. Different cyclization reactions of diketo-1,3-dioxinone **10**.



Scheme 4. Synthesis of (–)-montagnetol (**18**) and (+)-montagnetol (**2**). (see above-mentioned reference for further information.)

phenol in **17a** was of insufficient nucleophilicity. Consequently, a more classical approach was applied starting from the protected orsellinic acid **19**¹³ which underwent an esterification reaction with phenol **17a** or **17b** using activation with trifluoroacetic anhydride¹⁴ to provide the diesters **20a** and **20b**, respectively. Debenzoylation by hydrogenolysis afforded **21** and **3**, respectively (Scheme 5).



Scheme 5. Synthesis of (–)-erythrin (**21**) and (+)-erythrin (**3**). (see above-mentioned reference for further information.)

The two enantiomers of montagnetol, **18** and **2**, were examined for their optical rotations, compared with the natural product, showing **2** (2*R*,3*S*) to have the true configuration. Both enantiomers (–)-erythrin (**21**) and (+)-erythrin (**3**) were compared with an authentic sample of erythrin, and chiral HPLC analysis was fully consistent with the natural product configuration being (2*R*,3*S*)-erythrin (**3**).

Acknowledgments

We thank GlaxoSmithKline for the generous endowment (to A.G.M.B.), GlaxoSmithKline Verona for grant support (to J.F.B.), P. R. Haycock and R. N. Sheppard, both at Imperial College London, for high-resolution NMR spectroscopy and Professor V. Karunaratne (University of Peradeniya, Sri Lanka) for generously providing a sample of the natural product (+)-erythrin.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2009.11.134.

References and notes

- Choudhary, M. I.; Ali, S.; Thadani, V. M.; Karunaratne, V. U.S. Patent application 0,048,332 A1, 2009.
- Rao, S. V.; Seshadri, T. R. *Proc. Ind. Acad. Sci. Sect. A* **1941**, 13A, 199.
- Manaktala, S. K.; Neelakantan, S.; Seshadri, T. R. *Tetrahedron* **1966**, 22, 2373.
- Navarro, I.; Basset, J.-F.; Hebbe, S.; Major, S. M.; Werner, T.; Howsham, C.; Bräckow, J.; Barrett, A. G. M. *J. Am. Chem. Soc.* **2008**, 130, 10293.
- Hyatt, J. A.; Feldman, P. L.; Clemens, R. J. *J. Org. Chem.* **1984**, 49, 5105.
- This activated amide intermediate exists as a 1:1 mixture of keto and enol forms. As benzotriazole **9** is prone to decomposition, it was used directly in the next step. The NMR analysis of intermediate **9** was measured in THF-*d*₆.
- Katritzky, A. R.; Wang, Z.; Wang, M.; Hall, C. D.; Suzuki, K. J. *Org. Chem.* **2005**, 70, 4854.
- It was observed that the yield decreased if benzotriazole was not removed before column chromatography, due to aromatization to **11**. To avoid this side product, the mixture was washed with a pH 9 buffer solution to remove benzotriazole and suppress the rate of the aromatization reaction.
- The optical rotations of compounds **18** (2*S*,3*R*) and **2** (2*R*,3*S*) were $[\alpha]_D^{20} -10.1$ (acetone, *c* 0.5) and $[\alpha]_D^{20} =+11$ (acetone, *c* 0.4), respectively; these data were compared with those of the isolated natural (+)-montagnetol² $[\alpha]_D^{20} +12.6$ (acetone).
- Soriente, A.; De Rosa, M.; Trincone, A.; Sodano, G. *Bioorg. Med. Chem. Lett.* **1995**, 5, 2321.
- Compounds **16a** and **16b** are stable at room temperature, but are very sensitive to base or acid.
- Deuterium exchange occurs in methanol-*d*₄ leading to the disappearance of the keto-enol proton in the proton NMR spectrum.

13. Vicart, N.; Ortholand, J.-Y.; Emeric, G. Y.; Greiner, A. *Tetrahedron Lett.* **1994**, 35, 3917.
14. This is a modified procedure of: Wang, P.; Zhang, Z.; Yu, B. *J. Org. Chem.* **2005**, 70, 8884.
15. The optical rotations of compounds **21**, (2*S*,3*R*) and **3**, (2*R*,3*S*) were $[\alpha]_D^{20} -8.2$ (MeOH, *c* 0.2) and $[\alpha]_D^{20} +9$ (MeOH, *c* 0.2), respectively; these data were compared with those of the isolated natural (+)-erythrin, kindly provided by Professor V. Karunaratne, $[\alpha]_D^{20} +7.3$ (MeOH, *c* 0.2).